Iron Triangle Partners LP Cuts Stock Holdings in Twist Bioscience Corporation $TWST

Key Points

• Iron Triangle Partners LP reduced its holdings in Twist Bioscience Corporation by 13.9%, selling 68,558 shares, and now owns 423,913 shares valued at approximately $16.6 million.
• Twist Bioscience's stock has seen a 2.2% decline, currently trading at $26.59, with a market cap of $1.60 billion and a negative P/E ratio of -18.34.
• CEO Emily M. Leproust and CFO Adam Laponis both sold shares recently, indicating insider selling, with insiders collectively owning 3.01% of the stock.

Iron Triangle Partners LP cut its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 13.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 423,913 shares of the company's stock after selling 68,558 shares during the period. Twist Bioscience comprises approximately 2.7% of Iron Triangle Partners LP's portfolio, making the stock its 18th largest position. Iron Triangle Partners LP owned 0.71% of Twist Bioscience worth $16,643,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its holdings in Twist Bioscience by 18.5% during the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock worth $251,000 after purchasing an additional 1,006 shares during the last quarter. GAMMA Investing LLC raised its holdings in Twist Bioscience by 6,499.1% during the 1st quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock worth $1,153,000 after purchasing an additional 28,921 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Twist Bioscience during the 1st quarter worth approximately $396,000. SG Americas Securities LLC bought a new position in Twist Bioscience during the 1st quarter worth approximately $893,000. Finally, Stifel Financial Corp raised its holdings in Twist Bioscience by 19.6% during the 4th quarter. Stifel Financial Corp now owns 8,331 shares of the company's stock worth $387,000 after purchasing an additional 1,364 shares during the last quarter.

Twist Bioscience Stock Up 1.4%

NASDAQ TWST traded up $0.38 during mid-day trading on Friday, hitting $26.97. The company's stock had a trading volume of 1,199,807 shares, compared to its average volume of 1,956,522. The company's 50 day simple moving average is $32.75 and its 200 day simple moving average is $35.45. Twist Bioscience Corporation has a twelve month low of $24.28 and a twelve month high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -18.60 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Guggenheim reiterated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. JPMorgan Chase & Co. lowered their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group lowered their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the transaction, the chief executive officer directly owned 645,782 shares of the company's stock, valued at $23,093,164.32. The trade was a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,250 shares of company stock valued at $193,852. 3.01% of the stock is currently owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.